Article
First-in-human case report: AAV9-hGAA gene therapy for a patient with infantile-onset Pompe disease
2022-12-26
Abstract excerpt
<h4>Background</h4> The classic infantile-onset Pompe disease (IOPD) is characterized by cardiac hypertrophy, respiratory insufficiency, and rapidly progressive muscle weakness due to the acid alpha-glucosidase (GAA) deficiency. Enzyme replacement therapy (ERT) is the current approach for IOPD, but it entails several limitations. Aiming to overcome the limited efficiency of ERT, we developed adeno-associated virus...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 429b80ca-d72b-5681-ad65-f00bd13dced3
- DOI
- 10.1101/2022.12.22.22283398
